Group 1: Research Basic Information - The research object is Yangguang Nuoyue, belonging to the medical service industry, and the reception time is October 21, 2025 [17] - The listed company's reception staff includes the chairman, general manager, financial director, board secretary of Yangguang Nuoyue, the general manager of Langyan Life, and relevant personnel from the independent financial advisor and accounting firm [17] Group 2: Detailed Research Institutions - The reception objects include investors and others, and the reception object type is not clearly stated [20] Group 3: Research Institution Proportion - No specific content provided Group 4: Main Content Data - The company held an online performance briefing at the Shanghai Stock Exchange Roadshow Center, including management speeches and answering investor questions [24] - The significance of the reorganization for the company to improve its operating conditions: achieving industrial layout upgrade, significant synergy, accelerated strategic transformation, and dual improvement in performance and finance [24] - The company's long - term strategic positioning is to build a "R & D service + pipeline cultivation + new quality industrial chain" trinity business ecosystem and become an influential innovative drug R & D service enterprise [25] - Measures to improve company management and performance: perfecting performance appraisal indicators, deepening business structure upgrade, and using AI to empower R & D efficiency [25]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company plans to acquire 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. to accelerate its innovation transformation, enhancing industry competitiveness and profitability [1] - The acquisition will enable the company to incubate and implement self-developed products, leveraging its R&D advantages alongside Langyan's production and sales strengths, thus creating new profit growth points [1] - The company is focusing on building a business ecosystem that integrates "R&D services + pipeline cultivation + new quality industrial chain," with a strong emphasis on innovative drug development [3] Financial Performance - The company expects its net profit for 2025-2027 to be CNY 233 million, CNY 288 million, and CNY 355 million respectively, reflecting growth rates of 31.3%, 23.8%, and 23.0% [11] - Projected revenue for 2025 is CNY 1,291 million, with a year-on-year growth rate of 19.8% [12] - The company's earnings per share (EPS) is expected to reach CNY 2.08 in 2025, with a corresponding P/E ratio of 22.3 [12] Business Strategy - The company is actively increasing R&D investment and expanding its product pipeline, with several key products entering clinical trial phases [3] - A stock incentive plan has been proposed, granting 2.43% of the total shares to 127 key personnel, aimed at aligning their interests with the company's long-term performance [2] - The company is collaborating with Huawei Cloud to build a "polypeptide molecular large model platform," enhancing its capabilities in drug design and development [10]